Macropore Inc. IR-Pages
Twelve Peer Reviewed Papers Focused on MacroPore Products in Spinal Surgery
Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
MacroPore Announces Publication of Twelve Peer Reviewed Papers Focused on
MacroPore Products in Spinal Surgery
– Papers appear in Neurosurgical Focus, March 2004:
Bioabsorbable Devices in Spinal and Cranial Neurosurgery –
San Diego, March 17, 2004 – MacroPore Biosurgery, Inc. (Frankfurt Stock
Exchange: XMP) (MacroPore) announced today the publication of 12 scientific
papers citing HYDROSORB products in the March issue of the Neurosurgical Focus,
a peer reviewed on-line journal, available free of charge, which is published by
the Journal of Neurosurgery and American Association of Neurological Surgeons.
The issue was edited by Charles L. Branch Jr., MD, Chairman of the Department of
Neurosurgery at Wake Forest University, Baptist Medical Center in Winston-
Salem, North Carolina.
The 12 papers were contributed by 44 authors from 16 academic and medical
institutions. The studies demonstrate clinical follow-up with HYDROSORB products
for up to 32 months, with spinal fusion rates ranging from 94% to 100% of the
operated levels. These results were achieved in a range of challenging clinical
scenarios including multi-level fusion cases and patients with risk factors that
typically contribute to a higher incidence of non spinal fusion.
“These publications, which were all conducted by highly respected researchers,
provide further supporting clinical evidence for the use of MacroPore’s products
in spinal fusion” said Sharon Schulzki, Chief Operating Officer of MacroPore
Biosurgery. “The results are comparable to or better than those reported in the
literature for alternative materials, such as titanium and structural allograft
(cadaver) bone.”
HYDROSORB products offer surgeons advantages of initial and intermediate
stability during healing without the potential short and long-term complications
that are associated with alternative implant materials, such as titanium,
carbon fiber, and allograft bone. HYDROSORB products offer safe and predictable
performance, while eliminating the disadvantages of radiographic interference,
the formation of an intervening fibrous tissue layer, stress shielding, and long
term implant migration, all of which have been issues associated with the use
of metal. In comparison to structural allograft bone, HYDROSORB products provide
predictable resorption and bone remodeling, while avoiding issues related to
risk of disease transmission and limited supply.
HYDROSORB products are manufactured by MacroPore and distributed exclusively by
Medtronic Sofamor Danek, the global leader in the spine implant industry, and
have the CE mark for lumbar interbody fusion applications when used in
conjunction with rigid fixation devices.
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery (Frankfurt: XMP) (MacroPore) is focused on the discovery
and development of regenerative medicine technologies and therapies. We are
committed to improving the practice of medicine by creating innovative products
that address spine and orthopedic bone repair and cardiovascular tissue repair.
Our surgical implants, which represent one of the latest advancements in spine
and orthopedic medicine, are manufactured by MacroPore and distributed
exclusively through Medtronic Sofamor Danek. We are conducting research and
development for an autologous, homologous-use, cell-based technology for the
regeneration and repair of damaged tissues throughout the body. We are currently
targeting the repair of cardiovascular tissues that are damaged after a
myocardial infarction. For further information please visit our web site
http://www.macropore.com .
Contact:
MacroPore Biosurgery, Inc.
Tom Baker
Media & U.S. Investors
Tel. +1-858-458-0900
tbaker@macropore.com
MacroPore Biosurgery, Inc.
Stefanie Bacher
European Investors
Tel. +1-858-362-0365
sbacher@macropore.com
edicto GmbH
Axel Mühlhaus/Sönke Knop
European Investor &
Press Agency
Tel.: +49 (0) 60 84 94 85-90
kontakt@edicto.de
Cautionary Statement Regarding Forward-Looking Statements
This press release may include forward-looking statements regarding events and
trends which may affect MacroPore Biosurgery’s future operating results and
financial position. Such statements are subject to risks and uncertainties that
could cause MacroPore Biosurgery’s actual results and financial position to
differ materially. These risks and uncertainties are described (under the
heading “Risk Factors”) in our 2002 Annual Report which is available on our web
site. MacroPore Biosurgery assumes no responsibility to publicly release the
results of any revision of forward-looking statements to reflect events, trends
or circumstances after the date they are made.
end of message, (c)DGAP 17.03.2004
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
170830 Mär 04
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found